Bosentan for Mild Pulmonary Vascular Disease in Asd Patients.
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Volume overload due to left-to-right shunting in patients with atrial septal defect type
secundum causes pulmonary vascular disease over a long period of time. Pulmonary vascular
resistance can be assessed non-invasively using bicycle stress echocardiography. By measuring
cardiac output and pulmonary artery pressures at different stages of exercise, a
pressure-output plot can be obtained. The slope of the pressure-output plot reflects
pulmonary vascular resistance. In patients undergoing ASD repair after the age of 40 years,
pulmonary vascular resistance was higher when compared to age-matched controls, indicating
the presence of mild pulmonary vascular disease. Bosentan has been shown to decrease
pulmonary vascular resistance.
The investigators hypothesize that in patients with an ASD type secundum, who underwent ASD
repair after the age of 40 years, administration of bosentan decreases pulmonary vascular
resistance as assessed by bicycle stress echocardiography.